As it continues to confront a potential existential threat in the United States, CRDMO juggernaut WuXi AppTec’s finances certainly don’t seem to be feeling the pressure.
In the first nine months of 2026, the contract research, development and manufacturing organization reported sales of 45.54 billion Chinese yuan ($6.8 billion), up nearly 39% year over year, while revenue from continuing operations jumped more than 46%.
WuXi AppTec figures that momentum will continue over the next few months and is now raising its revenue target for the year from 58.5 billion to 60.5 billion yuan to a new range of 61 billion to 61.9 billion yuan, with the final range currently working out to roughly $9.1 billion to $9.3 billion in U.S. dollars.
“To efficiently meet our customers’ evolving needs, we are accelerating our global capacity development, enhancing our operational resilience, and driving high-quality growth, delivering even greater value for customers and shareholders alike,” Ge Li, Ph.D., WuXi AppTec’s chairman and CEO, said in a statement.
In another boon for the company, WuXi AppTec’s backlog for continuing operations has reached a value of 76.7 billion yuan ($11.5 billion), the helmsman added.
But a pivotal moment looms for WuXi AppTec toward the end of the year, when the U.S. Office of Management and Budget (OMB) is required to publish its initial list of "biotechnology companies of concern" under the Biosecure Act by Dec. 18. The list will draw, in part, from a separate roster of companies identified by the Defense Department as having ties to the Chinese military.
In June, the Defense Department added WuXi AppTec to its Section 1260H list of companies it believes have ties to the Chinese military while operating in the U.S. The designation subjected the company to federal defense contracting restrictions and raised the prospect of broader federal procurement and funding restrictions under the Biosecure Act, which became law in December 2025.
WuXi AppTec has vehemently denied the claims about its alleged ties to the Chinese military, telling Fierce earlier this year that it viewed its inclusion on the list as “clearly a mistake.” The company sued following the designation and secured a win in August when the U.S. District Court for the District of Columbia granted its motion for a preliminary injunction, temporarily blocking the DOD from enforcing or giving effect to the Section 1260H designation.
WuXi AppTec knows, however, that it isn’t completely out of the woods yet and could still be named a company of concern, the CRDMO’s general counsel said on a Monday call with investors, as cited by Pharma Manufacturing.
In breaking down its earnings for the first nine months of 2026, WuXi AppTec noted that its CDMO services grew 51.5% year over year to 39.36 billion yuan ($5.9 billion), which it credited to the ramp-up of new capacity throughout 2025 and the shift of projects in the hopper into later stages.
On the topic of manufacturing real estate, WuXi AppTec said it is also upping the amount it has earmarked to spend on capex this year to upwards of 8.5 billion yuan (around $1.3 billion), which is being used in part to hasten work on a new site in Changzhou, China, ahead of schedule.
The company’s testing services business, meanwhile, grew sales 32% year over year to 3.91 billion yuan (a little more than $586 million) in the first nine months of 2026, WuXi AppTec said in an earnings slide deck.
WuXi AppTec did not use the occasion of its earnings release to disclose a geography-by-geography breakdown of its performance.
The U.S. has remained an important source of business for the company, despite recent policy pressures; Last year, WuXi AppTec noted that of 209 new integrated projects it added in 2025, roughly half came from the United States.